Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 3
1946 1
1947 3
1948 1
1949 2
1950 2
1951 5
1952 3
1953 5
1955 2
1957 1
1959 1
1960 3
1961 2
1962 4
1968 1
1973 1
1976 1
1984 1
1989 2
1990 2
1992 2
1993 4
1994 4
1995 2
1996 6
1997 6
1998 4
1999 6
2000 5
2001 3
2002 3
2003 8
2004 3
2005 12
2006 5
2007 7
2008 9
2009 7
2010 13
2011 9
2012 15
2013 14
2014 15
2015 13
2016 19
2017 12
2018 16
2019 22
2020 18
2021 14
2022 6
2023 11
2024 10
2025 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

327 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
Geyer CE Jr, Untch M, Huang CS, Mano MS, Mamounas EP, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, D'Hondt V, Conlin AK, Guarneri V, Wapnir IL, Jackisch C, Arce-Salinas C, Fasching PA, DiGiovanna MP, Crown JP, Wuelfing P, Shao Z, Rota Caremoli E, Bonnefoi HR, Hennessy BT, Stamatovic L, Castro-Salguero H, Brufsky AM, Knott A, Siddiqui A, Lambertini C, Boulet T, Nyawira B, Restuccia E, Loibl S; KATHERINE Study Group. Geyer CE Jr, et al. N Engl J Med. 2025 Jan 16;392(3):249-257. doi: 10.1056/NEJMoa2406070. N Engl J Med. 2025. PMID: 39813643 Clinical Trial.
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M; PALOMA3 Study Group. Turner NC, et al. N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1. N Engl J Med. 2015. PMID: 26030518 Free article. Clinical Trial.
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. Perren TJ, et al. N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. N Engl J Med. 2011. PMID: 22204725 Free article. Clinical Trial.
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, Bellet M, Cortés J, Elliott R, Pancholi S, Baselga J, Dowsett M, Martin LA, Turner NC, Serra V. Herrera-Abreu MT, et al. Among authors: martin la. Cancer Res. 2016 Apr 15;76(8):2301-13. doi: 10.1158/0008-5472.CAN-15-0728. Epub 2016 Mar 28. Cancer Res. 2016. PMID: 27020857 Free PMC article.
Mitochondrial cholesterol import.
Elustondo P, Martin LA, Karten B. Elustondo P, et al. Among authors: martin la. Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Jan;1862(1):90-101. doi: 10.1016/j.bbalip.2016.08.012. Epub 2016 Aug 23. Biochim Biophys Acta Mol Cell Biol Lipids. 2017. PMID: 27565112 Review.
Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast Cancer.
Gemma C, Lai CF, Singh AK, Belfiore A, Portman N, Milioli HZ, Periyasamy M, Raafat S, Nicholls AJ, Davies CM, Patel NR, Simmons GM, Fan H, Nguyen VTM, Magnani L, Rakha E, Martin LA, Lim E, Coombes RC, Pruneri G, Buluwela L, Ali S. Gemma C, et al. Among authors: martin la. Cancer Res. 2024 Dec 16;84(24):4283-4297. doi: 10.1158/0008-5472.CAN-24-0013. Cancer Res. 2024. PMID: 39356622 Free PMC article.
327 results